Evidence map›Paper›PMID 42557320›Full record

ArticleNature2026

A tumour-derived organoid biobank maps cancer gene dependencies.

C Herranz-Ors, S G Bhosle, A E Beck, J G R Gilbert, G Picco, J Espejo Valle-Inclan, F Muyas, S Valentini, A E Andres, R Ansari and 80 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

90 authors.

C Herranz-OrsWellcome Sanger Institute, Cambridge, UK.
S G BhosleWellcome Sanger Institute, Cambridge, UK.ORCID http://orcid.org/0000-0002-7638-2899
A E BeckWellcome Sanger Institute, Cambridge, UK.
J G R GilbertWellcome Sanger Institute, Cambridge, UK.ORCID http://orcid.org/0000-0001-8079-3159
G PiccoWellcome Sanger Institute, Cambridge, UK.
J Espejo Valle-InclanEuropean Molecular Biology Laboratory, European Bioinformatics Institute, Cambridge, UK.ORCID http://orcid.org/0000-0002-4857-5984
F MuyasEuropean Molecular Biology Laboratory, European Bioinformatics Institute, Cambridge, UK.
S ValentiniWellcome Sanger Institute, Cambridge, UK.
A E AndresWellcome Sanger Institute, Cambridge, UK.
R AnsariWellcome Sanger Institute, Cambridge, UK.
S BarthorpeWellcome Sanger Institute, Cambridge, UK.
G BattarbeeWellcome Sanger Institute, Cambridge, UK.
C M BeaverWellcome Sanger Institute, Cambridge, UK.
S BrocklesbyWellcome Sanger Institute, Cambridge, UK.ORCID http://orcid.org/0009-0006-9090-6907
J CantwellWellcome Sanger Institute, Cambridge, UK.
C A CollinsWellcome Sanger Institute, Cambridge, UK.
J DavisWellcome Sanger Institute, Cambridge, UK.
H G DimitrovaWellcome Sanger Institute, Cambridge, UK.
J DoranWellcome Sanger Institute, Cambridge, UK.
E EfendiWellcome Sanger Institute, Cambridge, UK.ORCID http://orcid.org/0009-0009-1217-7587
K EvansWellcome Sanger Institute, Cambridge, UK.
M FekryWellcome Sanger Institute, Cambridge, UK.
T A FowlerWellcome Sanger Institute, Cambridge, UK.
M Garcia-CasadoWellcome Sanger Institute, Cambridge, UK.
J A T GriffithsWellcome Sanger Institute, Cambridge, UK.
C HallWellcome Sanger Institute, Cambridge, UK.
R HamerWellcome Sanger Institute, Cambridge, UK.
C HardyWellcome Sanger Institute, Cambridge, UK.
Z HewitsonWellcome Sanger Institute, Cambridge, UK.
E HitchWellcome Sanger Institute, Cambridge, UK.ORCID http://orcid.org/0009-0000-0652-0814
L HollandWellcome Sanger Institute, Cambridge, UK.
D A JacksonWellcome Sanger Institute, Cambridge, UK.
N JoshiWellcome Sanger Institute, Cambridge, UK.
A KavasakaliWellcome Sanger Institute, Cambridge, UK.
L LetchfordWellcome Sanger Institute, Cambridge, UK.
H B LightfootWellcome Sanger Institute, Cambridge, UK.
H LingalaWellcome Sanger Institute, Cambridge, UK.
I MaliWellcome Sanger Institute, Cambridge, UK.
K MayWellcome Sanger Institute, Cambridge, UK.ORCID http://orcid.org/0000-0002-7307-6976
T MironenkoWellcome Sanger Institute, Cambridge, UK.
J MorrisWellcome Sanger Institute, Cambridge, UK.ORCID http://orcid.org/0000-0003-3934-0937
C PaciniWellcome Sanger Institute, Cambridge, UK.ORCID http://orcid.org/0000-0001-7791-0940
S PriceWellcome Sanger Institute, Cambridge, UK.
G Robert-TissotWellcome Sanger Institute, Cambridge, UK.
H A RogersWellcome Sanger Institute, Cambridge, UK.
J V SmithWellcome Sanger Institute, Cambridge, UK.ORCID http://orcid.org/0009-0005-4258-8150
K SmithWellcome Sanger Institute, Cambridge, UK.ORCID http://orcid.org/0009-0000-2198-2734
E SousterWellcome Sanger Institute, Cambridge, UK.
W J SpenceWellcome Sanger Institute, Cambridge, UK.
F ThomasWellcome Sanger Institute, Cambridge, UK.
S F VieiraWellcome Sanger Institute, Cambridge, UK.ORCID http://orcid.org/0000-0002-1021-3021
S WalkerWellcome Sanger Institute, Cambridge, UK.
G AlfonsinWellcome Sanger Institute, Cambridge, UK.
H BerminghamUniversity Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
H ColesEarly Cancer Institute, University of Cambridge, Cambridge, UK.ORCID http://orcid.org/0009-0003-1523-6905
D P EnnisDepartment of Surgery and Cancer, Imperial College London, London, UK.ORCID http://orcid.org/0000-0001-5260-3506
A FreemanEarly Cancer Institute, University of Cambridge, Cambridge, UK.ORCID http://orcid.org/0000-0002-8376-7498
G GiannoneDepartment of Surgery and Cancer, Imperial College London, London, UK.ORCID http://orcid.org/0000-0003-1991-039X
N GrehanEarly Cancer Institute, University of Cambridge, Cambridge, UK.
E A GriffithsUniversity Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
J HallCancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Cambridge, UK.ORCID http://orcid.org/0000-0002-8124-5434
S L LeeSchool of Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton, UK.
E Y L LeungUniversity Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.ORCID http://orcid.org/0000-0001-9748-7270
C LorenoEarly Cancer Institute, University of Cambridge, Cambridge, UK.
C MillingtonUniversity Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
A MirnezamiSchool of Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton, UK.
B NutzingerEarly Cancer Institute, University of Cambridge, Cambridge, UK.
K OrzechowskaDepartment of Cancer and Genomic Sciences, College of Medicine and Health, University of Birmingham, Birmingham, UK.
C M A PinnaDepartment of Cancer and Genomic Sciences, College of Medicine and Health, University of Birmingham, Birmingham, UK.ORCID http://orcid.org/0000-0002-5618-7842
A M RedmondEarly Cancer Institute, University of Cambridge, Cambridge, UK.ORCID http://orcid.org/0000-0001-9070-1780
K RobertsUniversity Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
S RoySchool of Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton, UK.
D A SandersCancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Cambridge, UK.
P TaniereUniversity Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
M ViasCancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Cambridge, UK.
K WanigasooriyaUniversity Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
OCCAMS Consortium
M R StrattonWellcome Sanger Institute, Cambridge, UK.ORCID http://orcid.org/0000-0001-6035-153X
L M StaudtLymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
U McDermottWellcome Sanger Institute, Cambridge, UK.ORCID http://orcid.org/0000-0001-9032-4700
J D BrentonCancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Cambridge, UK.
I A McNeishDepartment of Surgery and Cancer, Imperial College London, London, UK.ORCID http://orcid.org/0000-0002-9387-7586
A BiankinSchool of Cancer Sciences, University of Glasgow, Glasgow, UK.ORCID http://orcid.org/0000-0002-0362-5597
O J SansomSchool of Cancer Sciences, University of Glasgow, Glasgow, UK.ORCID http://orcid.org/0000-0001-9540-3010
I Cortes-CirianoWellcome Sanger Institute, Cambridge, UK.ORCID http://orcid.org/0000-0002-2036-494X
T J UnderwoodSchool of Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton, UK.
R C FitzgeraldEarly Cancer Institute, University of Cambridge, Cambridge, UK.ORCID http://orcid.org/0000-0002-3434-3568
A D BeggsUniversity Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.ORCID http://orcid.org/0000-0003-0784-2967
H E FranciesWellcome Sanger Institute, Cambridge, UK.
M J GarnettWellcome Sanger Institute, Cambridge, UK. mg12@sanger.ac.uk.ORCID http://orcid.org/0000-0002-2618-4237

Funding

Wellcome Trust
6 · The paper itself

Abstract

Cancer cell lines remain foundational for research and drug discovery, yet they incompletely capture tumour diversity, lack linked patient context, and have undergone adaptation to culture. Tumour organoids are three-dimensional cultures derived from patient tissue that offer a powerful complement to cell lines

Indexed as

Biological Specimen BanksGenes, NeoplasmNeoplasmsOrganoidsAllelesColorectal NeoplasmsCRISPR-Cas SystemsErbB ReceptorsFemaleGenes, EssentialHumansPrecision MedicineProto-Oncogene Proteins p21(ras)ras ProteinsErbB ReceptorsKRAS protein, humanProto-Oncogene Proteins p21(ras)ras Proteins

Identifiers

PMID42557320
PMCPMC13581617

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.